Table 2.

PASI and DLQI scores at week 28, week 108 and EOS

Pre‐dose	n	PASI score	DLQI
Week 28
Total	127	1.00 (0.00–2.60)	1.0 (0.0–2.0)
210 mg Q2W	54	0.85 (0.00–2.40)	1.0 (0.0–2.0)
140 mg Q2W	25	1.20 (0.00–2.40)	1.0 (0.0–3.0)
140 mg Q4W	48	1.20 (0.00–2.70)	1.0 (0.0–1.0)
Week 108
Total	122	0.20 (0.00–1.20)	0.0 (0.0–1.0)
210 mg Q2W	67	0.20 (0.00–1.50)	0.0 (0.0–1.0)
140 mg Q2W	41	0.20 (0.00–1.10)	0.0 (0.0–1.0)
140 mg Q4W	14	0.55 (0.00–1.40)	0.0 (0.0–1.0)
EOS after week 108
Total	107	0.00 (0.00–0.50)	0.0 (0.0–1.0)
210 mg Q2W	107	0.00 (0.00–0.50)	0.0 (0.0–1.0)

Each dose shows the last dose before each point. Data are presented as numbers or median (interquartile range). DLQI, Dermatology Life Quality Index; EOS, end of study; PASI, Psoriasis Area and Severity Index; Q2W, every 2 weeks; Q4W, every 4 weeks.